Basilea Pharmaceutica stock analysis
Basilea Pharmaceutica (BPMUF) Stock Price & Analysis
BPMUF Stock Chart & Stats
- Day’s Range
- $81.85 - $89.90
- 52-Week Range
- $48.35 - $93.00
- Previous Close
- $88.15
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $1.07B
- Enterprise Value
- $644.92M
- Total Cash (Recent Filing)
- $175.98M
- Total Debt (Recent Filing)
- $83.44M
- Price to Earnings (P/E)
- 16.9
- Beta
- -0.01
- Next Earnings
- Feb 16, 2027 (Est.)
- EPS Estimate
- 5.13
- Last Dividend Ex-Date
- Apr 11, 2013
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Growth And Raised Guidance
Higher commercial revenue expectations and upgraded operating-profit guidance indicate stronger underlying demand for Basilea’s marketed portfolio. Continued growth in Cresemba and Zevtera-related income can support recurring royalties, product revenue, and operating leverage over the next several quarters.
Strong Cash Generation And Funding
Robust operating and free cash flow gives Basilea internal funding capacity for clinical development and commercial investment. The improved net-cash position and substantial nondilutive support reduce dependence on equity financing while allowing the company to advance its pipeline.
Advancing Anti-infective Pipeline
Multiple programs progressing through late-stage and early clinical development broaden Basilea’s future product opportunity beyond current commercial medicines. Phase III advancement and new clinical starts provide potential catalysts for durable portfolio expansion, subject to execution and regulatory outcomes.
Bears Say
Volatile Profitability
The sharp change in net margin shows that reported profitability can vary materially despite strong gross economics. Sensitivity to product mix, milestones, and one-off items makes earnings less predictable and may limit the consistency of operating leverage across reporting periods.
Clinical And Regulatory Execution Risk
Key pipeline value depends on late-stage trial execution, regulatory clarity, and eventual approval timing. Delayed readouts or additional pivotal requirements could postpone commercialization and revenue realization, while increasing development costs before these programs can contribute materially.
Convertible Bond Maturity
The upcoming convertible maturity creates a defined financing obligation that will compete with pipeline investment and other capital-allocation priorities. Although Basilea has reduced the outstanding balance, repayment or refinancing requirements could reduce financial flexibility over the medium term.
Basilea Pharmaceutica News
BPMUF FAQ
What was Basilea Pharmaceutica’s price range in the past 12 months?
What is Basilea Pharmaceutica’s market cap?
When is Basilea Pharmaceutica’s upcoming earnings report date?
How were Basilea Pharmaceutica’s earnings last quarter?
Is Basilea Pharmaceutica overvalued?
Does Basilea Pharmaceutica pay dividends?
What is Basilea Pharmaceutica’s EPS estimate?
How many shares outstanding does Basilea Pharmaceutica have?
What happened to Basilea Pharmaceutica’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Basilea Pharmaceutica?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Basilea Pharmaceutica
Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise, concentrating its efforts on inventing and advancing treatments to address critical unmet medical needs within the therapeutic fields of oncology and anti-infectives. Its commercialized offerings include Cresemba, an azole antifungal drug available in both intravenous and oral formulations, utilized for managing invasive aspergillosis and mucormycosis in the United States and the European Union; this drug is also advancing through Phase III clinical trials in Japan for various invasive fungal infections. The company additionally provides Zevtera, an antibiotic targeting community and hospital-acquired pneumonia, which is also undergoing Phase III clinical development for acute bacterial skin and skin structure infections, along with Staphylococcus aureus bacteremia. Beyond its current portfolio, Basilea's pipeline features Derazantinib, a small molecule inhibitor in Phase 2 clinical trials for bile duct cancer, and in Phase 1/2 trials for both bladder and stomach cancers, as well as Lisavanbulin, a novel tumor checkpoint controller drug. Established in 2000, Basilea Pharmaceutica AG maintains its corporate headquarters in Basel, Switzerland.
- Sector
- General
- Industry
- Biotechnology
- CEO
- David Veitch
- Employees
- 200
- Website
- www.basilea.com
- Address
- Hegenheimermattweg 167b, Allschwil, BL, 4123, CH
Basilea Pharmaceutica (BPMUF) Earnings & Revenues
BPMUF Earnings Call
Earnings Call SentimentPositive
The call presented a strongly positive operational and financial picture: double-digit revenue growth, a materially higher operating profit, strengthened cash position, increased non-dilutive funding, and clear pipeline progression (two Phase III assets and new first-in-human study). Management raised full-year guidance and reiterated multi-year value creation (Agenda 2030). Key challenges are execution and timing risks around late-stage clinical readouts and regulatory clarity, increased R&D spend and near-term operating expense pressure, working capital timing effects on cash flow, and a convertible bond maturing in 2027. On balance, the positive commercial momentum, funding awards, guidance upgrades and pipeline advancement outweigh the near-term costs and timing uncertainties.
View all BPMUF earnings summariesBPMUF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 6 | 5 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 8 | 0 | 4 |
